← All trials
NCT05063786
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 14, 2021
- Primary completion
- Jul 31, 2026
- Completion date
- Jul 31, 2026
- First posted
- Oct 1, 2021
- Last posted
- Nov 11, 2021
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Spanish Breast Cancer Research GroupLead sponsor
- NovartisCollaborator
- University of MilanCollaborator
- University of MilanStudy director
- University of TorontoStudy director
- University of ValenciaStudy director
- ETOP IBCSG Partners FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.